COMMUNIQUÉS West-GlobeNewswire

Abivax publishes financial reports with the French and U.S. securities regulatory agencies
26/03/2025
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a [...]
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
26/03/2025
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission [...]
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
26/03/2025
Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels [...]
Tilray Successfully Prevails with Dismissal of HEXO Shareholder Lawsuit
26/03/2025
NEW YORK and LEAMINGTON, Ontario, March 26, 2025 (GLOBE NEWSWIRE) -- Tilray Brands Inc. (“ Tilray ”) (Nasdaq: TLRY; TSX: TLRY), and its subsidiary HEXO Corporation (“ HEXO ”), announced the successful dismissal of the [...]
BioCardia Reports 2024 Business Highlights and Financial Results
26/03/2025
SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results
26/03/2025
Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader [...]
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
26/03/2025
WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on [...]
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
26/03/2025
Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC who had an inadequate response to ICI treatment, failed several chemotherapy [...]
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
26/03/2025
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e – - Both groups demonstrated [...]
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
26/03/2025
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year [...]
Dyadic Reports 2024 Year-End Financial Results and Business Updates
26/03/2025
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024 Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 [...]
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
26/03/2025
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies [...]
CRISPR Therapeutics Announces Transition of Chief Operating Officer
26/03/2025
ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today [...]
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
26/03/2025
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications [...]
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
26/03/2025
FDA Approval of Emrosi™ ( 40 mg Minocycline Hydrochloride Modified-Release Capsules ) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 [...]
Inventiva reports its 2024 full year results and provides a business update
26/03/2025
Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 [...]
Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité
26/03/2025
Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024 Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024 Levée d’un produit brut de 116 millions d’euros dans le cadre de la [...]
Heartflow Closes $98 Million Convertible Notes Financing
26/03/2025
Additional Capital to Support Broadening Adoption of a Leading Platform That Transforms Diagnosis and Management of Coronary Artery Disease MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. , the [...]
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
26/03/2025
WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug [...]

Pages